Pharmalive - The Pulse of the Pharmaceutical Industry


Search Criteria: Search In:  
Special Reports Conferences

Browse Categories
Biotech Companies
Brands
DTC Advertising
Healthcare Agencies
Japanese Pharma Companies
Life Sciences Investment
Medical Device Companies
New Drugs
Personnel and Leadership
Pharma Companies
Pipelines
Specialty Pharma Companies
Therapeutic Categories

Featured Report

Price: $355.00
Published: 02/2010
Format: PDF
Total pages: 110

Biotech/Biopharma/Biosimilar Review and Outlook 2010

Introductory rate of $355 expires 3/26/10. Save $70 off the regular rate of $425. Click the sample link below to view the complete table of contents and select pages.

The biotechnology industry was eager to leave behind 2009 and the negative effects of the global economic recession that impacted even some of the premiere biotech players. Positive notes from the past year included a record total value for partnership deals during one of the most-difficult financing environments ever, and the industry hopes to keep up that pace during 2010. The biotech corporations that survived the challenging financial climate will have to continue adapting to fast-changing surroundings.

Also acclimating to the altering business conditions is Big Pharma. Three prime-time deals were made during 2009 by pharma leaders, and each of the acquired companies possessed valuable biotech/biological product assets. Some major pharma companies are in the process of transforming their operations via a biopharmaceutical business model to remain competitive against the rapidly growing generics market. Meanwhile, Big Pharma and Big Biotech will continue to compete for smaller companies armed with advanced product pipelines and significant technologies.

2010 appears to be the year that a U.S. regulatory pathway for biosimilars/follow-on biologics is finally established. House and Senate bills are shaping the much-anticipated outcome regarding the length of patent protection for biotech drugs, which most likely will fall in the 10-to-12 year range.

Prescription-drug pipeline for the biotech industry detail the following for
each product:
• Each pipeline products’ chemical or substance composition, intended
indication, class of drug, clinical status, region of development, and the
product developer/intended marketer
• Pipeline status details preclinical development, Phase I, Phase I/II, Phase II, Phase II/
III, Phase III, and awaiting approval
• Region of development includes the United States, Europe, and Japan


view sample | View TOC | add to cart


Search for a Report

Build Reports On Demand
PharmaLive OnDemand Special Reports allow users to generate custom reports by selecting only the data they need. The report cost is based on the amount of data selected.

Choose a starting point below and click "Create Report". As you move through the selection process, you will be able to create additional filters.

Company Report
Disease/Medical Usage Report
Therapeutic Category Report
Phase of Development Report

Biotech Companies View All
Biotech/Biopharma/Biosimilar Review and Outlook 2010

Mergers & Acquisitions, Partnerships, & Collaborations 2010 - Review and Outlook


Brands View All
Top 500 Prescription Medicines 2009

Combo Report, Drugs in the Pipeline and on the Market


DTC Advertising View All
Report Combo: New Drugs Outlook, Direct-to-Consumer, and Advertising Account Rosters: Healthcare Marketing Communications Agencies

Direct-to-Consumer Advertising: Analysis of DTC Spend by Brand, Company, and Media


Healthcare Agencies View All
Report Combo: New Drugs Outlook, Direct-to-Consumer, and Advertising Account Rosters: Healthcare Marketing Communications Agencies

Account Rosters: Healthcare Marketing Communications Agencies 2009


Japanese Pharma Companies View All
Top 20 Japanese Companies and Their Pipelines 2009

Top Company Combination: Top 50 Pharma, Top 50 Biotech, Top 50 Specialty Companies, and Top 15 Japanese Pharma Companies


Life Sciences Investment View All
Biotech/Biopharma/Biosimilar Review and Outlook 2010

Global Bioscience Private Venture Investment Review: 2Q09 & 1H09 Trend Analysis


Medical Device Companies View All
Mergers & Acquisitions, Partnerships, & Collaborations 2010 - Review and Outlook

Top Companies Review: Business Overview and Outlook Top 50 Pharmaceutical Companies and Their Pipelines, Top 50 Biotechnology Companies and Their Pipelines , and Top 100 Medical Device Companies


New Drugs View All
Report Combo: New Drugs Outlook, Direct-to-Consumer, and Advertising Account Rosters: Healthcare Marketing Communications Agencies

Drugs in Development: From Pipeline to Market 2009


Personnel and Leadership View All
People on the Move: First-Third Quarters 2009

People on the Move: Third-Quarter 2009


Pharma Companies View All
Biotech/Biopharma/Biosimilar Review and Outlook 2010

Mergers & Acquisitions, Partnerships, & Collaborations 2010 - Review and Outlook


Pipelines View All
Biotech/Biopharma/Biosimilar Review and Outlook 2010

Weight-Management Outlook 2010


Specialty Pharma Companies View All
Mergers & Acquisitions, Partnerships, & Collaborations 2010 - Review and Outlook

Top 50 Specialty Companies 2009


Therapeutic Categories View All
Weight-Management Outlook 2010

Therapeutic Category Review and Outlook




©2010 Canon Communications Pharmaceutical Media Group